News & Updates
Filter by Specialty:

PLD-apatinib combo show promise for ovarian cancer
A combination regimen comprising apatinib, a small-molecule TKI*, and pegylated liposomal doxorubicin (PLD) led to improved progression-free survival (PFS) in women with platinum-resistant recurrent ovarian cancer (PROC), results of the APPROVE trial suggest.
PLD-apatinib combo show promise for ovarian cancer
03 Oct 2022
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
27 Sep 2022
Does frozen embryo transfer up hypertension risk during pregnancy?
The risk of hypertensive disorders in pregnancy (HDP) is increased following assisted reproductive technology (ART) using frozen embryo transfer (FET) compared with after fresh embryo transfer or natural conception, according to results of a study presented at ESHRE 2022.
Does frozen embryo transfer up hypertension risk during pregnancy?
25 Sep 2022
POP: Delayed intake, missing one pill not a major reason for contraceptive failure
Delayed intake of a progestogen-only pill (POP) or missing one pill does not necessarily reduce its theoretical contraceptive protection, with little effect on cervical mucus and ovulation, as shown in a study.